Purple Squirrel Economics, Montreal H3J 1M1, Canada.
Pfizer Inc., New York, NY 10017, USA.
J Comp Eff Res. 2021 May;10(7):603-612. doi: 10.2217/cer-2020-0280. Epub 2021 Mar 18.
Two combination therapies recently approved and recommended for use in combination with low-dose cytarabine (LDAC) in acute myeloid leukemia patients unfit for intensive chemotherapy are glasdegib+LDAC and venetoclax+LDAC. An indirect treatment comparison used median overall survival, overall survival hazard ratios, complete remission (CR), CR+CR with incomplete blood count recovery and transfusion independence to assess comparative effectiveness, and a simulated treatment comparison accounted for differences in patient characteristics between trials. Differences in efficacy between glasdegib+LDAC and venetoclax+LDAC were suggestive and not statistically significant. With no significant differences in comparative effectiveness, considerations such as safety profiles, burden of administration and patient preference are likely to guide treatment decisions.
两种联合疗法最近被批准并推荐与低剂量阿糖胞苷（LDAC）联合用于不适合强化化疗的急性髓系白血病患者，分别是glasdegib+LDAC 和 venetoclax+LDAC。间接治疗比较使用中位总生存期、总生存风险比、完全缓解（CR）、CR+不完全血细胞计数恢复的 CR 和输血独立性来评估疗效，模拟治疗比较考虑了试验之间患者特征的差异。glasdegib+LDAC 和 venetoclax+LDAC 之间的疗效差异具有提示性，但没有统计学意义。在没有显著疗效差异的情况下，安全性特征、管理负担和患者偏好等因素可能会指导治疗决策。
